Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure

Abstract

In patients with NYHA class II or III CHF and LVEF of 35 percent or less, amiodarone has no favorable effect on survival, whereas single-lead, shock-only ICD therapy reduces overall mortality by 23 percent.